Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion

Deletion of 17p (TP53) identifies a rare subset of chronic lymphocytic leukaemia (17p‐ CLL) with aggressive behaviour. Genome‐wide DNA‐profiling was performed to investigate 18 patients with 17p‐ CLL. All cases had multiple copy‐number (CN) changes. Among the several recurrent CN changes identified, 8q24.13‐q24.1‐gain (MYC), 8p‐loss (TNFRSF10A/B, also known as TRAIL1/2) and 2p16.1‐p14‐gain (REL/BCL11A) appeared frequently represented. 8p‐loss and 2p16.1‐p14‐gain also appeared clinically relevant and predicted significant shorter time from diagnosis to treatment (8p‐loss) and overall survival (8p‐loss and 2p16.1‐p14‐gain, P < 0·05). These observations document a highly unstable genome in 17p‐ CLL and suggest that additional genes outside the TP53 locus may be important for tumour behaviour.

[1]  D. Weisenburger,et al.  Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia , 2007, Cell.

[2]  L. Staudt,et al.  Characterization of 8 p 21 . 3 chromosomal deletions in B-cell lymphoma : TRAIL-R 1 and TRAIL-R 2 as candidate dosage-dependent tumor suppressor genes , 2005 .

[3]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[4]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[5]  Bernhard Radlwimmer,et al.  A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. , 2006, American journal of human genetics.

[6]  M. Kaminski,et al.  Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.

[7]  H. Tagawa,et al.  Characterization of target genes at the 2p15–16 amplicon in diffuse large B‐cell lymphoma , 2006, Cancer science.

[8]  Markus Schilhabel,et al.  Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. , 2005, Blood.

[9]  R. Siebert,et al.  Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. , 2001, Blood.

[10]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Döhner,et al.  Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Gunnar Wrobel,et al.  Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jens Timmer,et al.  Using High-density Snp Arrays Genome-wide Analysis of Dna Copy Number Changes and Loh in Cll , 2022 .

[14]  Francesco Bertoni,et al.  High density genome‐wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia , 2008, British journal of haematology.

[15]  Tait D. Shanafelt,et al.  Loss of TP53 is due to rearrangements involving chromosome region 17p10∼p12 in chronic lymphocytic leukemia , 2006 .

[16]  Daniel L Van Dyke,et al.  Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. , 2006, Cancer genetics and cytogenetics.